

Attorney Docket No. P33037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Damiani et al. June 9, 2008  
Serial No.: 10/511,769 Group Art Unit No.: 1625  
Filed: May 2, 2005 Examiner: C. C. Chang  
For: COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND  
USE THEREOF IN THERAPY

Information Disclosure Statement Under 37 C.F.R. §1.97(c)


The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the **\$180.00** fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 10/511,769  
Group Art Unit No.: 1625

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 2705023  
Facsimile (610) 270-5090  
N:\DMF\cases\P33037\IDS\_FEE\_REQUIRED.doc